Taken together, these findings indicate that increased expression of FOSL1 enhances the aggressiveness of AM by modulating the cell cycle and EMT, which might serve as a novel target for AM treatment. The gene discussed is FOSL1; the disease is acute myeloblastic leukemia with maturation.